Summary.It is unknown whether bone changes which can occur in multiple myeloma (MM) are due to cytokineinduced osteoclastic bone resorption from a clone of abnormal plasma cells or high-dose glucocorticoid therapy.We studied 25 MM patients treated for 1-12 years with combination chemotherapy, subdivided into two groups. Group 1 consisted of 12 patients with stage I and II myeloma and group 2 consisted of 13 patients with stage III MM. Their serum biochemistry, tetracycline-labelled bone histomorphometry and bone densitometry were compared to age-and sex-matched controls.Patients with MM demonstrated increased indices of bone resorption (P < 0 : 001 versus controls) and, to a lesser extent, increased indices of bone formation (P < 0 : 01 versus controls). No patient had evidence of a mineralization defect.Lumbar spine, femoral neck and total body bone mineral density measurements (BMD) were significantly lower in group 2 compared with group 1 (P < 0 : 05). Following 12 months of therapy, lumbar spine BMD decreased by 6 : 6% (95% CI, 2 : 7% to ¹9 : 3%) and femoral neck BMD decreased by 9 : 5% (95% CI, ¹3 : 2% to ¹15 : 9%). In a stepwise regression analysis, cumulative prednisolone dosage (B Coef: ¼ ¹0 : 39; P ¼ 0 : 03) and plasma cell infiltrate (B Coef: ¼ ¹0 : 08; P ¼ 0 : 05) were the most important predictors of lumbar spine bone loss, whereas serum paraprotein (B Coef: ¼ ¹0 : 35; P ¼ 0 : 02) and plasma cell infiltrate (B Coef: ¼ ¹0 : 20; P ¼ 0 : 04) were the most important predictors of femoral neck bone loss.We conclude that MM is characterized by high bone turnover with osteoblast-osteoclast uncoupling. Both disease activity and high-dose glucocorticoid therapy may be responsible for the ongoing bone loss seen with MM.